🇺🇸 FDA
Pipeline program

Rivastigmine

CENA713DIN01

Approved small_molecule completed

Quick answer

Rivastigmine for Alzheimer's Disease is a Approved program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Alzheimer's Disease
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials